Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · IEX Real-Time Price · USD
35.58
+1.27 (3.70%)
At close: Apr 18, 2024, 4:00 PM
34.87
-0.71 (-2.00%)
After-hours: Apr 18, 2024, 4:06 PM EDT
Spyre Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Spyre Therapeutics stock have an average target of 38, with a low estimate of 31 and a high estimate of 54. The average target predicts an increase of 6.80% from the current stock price of 35.58.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SYRE stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Reiterates $36 → $54 | Strong Buy | Reiterates | $36 → $54 | +51.77% | Mar 26, 2024 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $12 → $35 | Hold → Buy | Upgrades | $12 → $35 | -1.63% | Mar 1, 2024 |
| BTIG | BTIG | Strong Buy Initiates $32 | Strong Buy | Initiates | $32 | -10.06% | Dec 20, 2023 |
| Stifel | Stifel | Strong Buy Maintains $23 → $27 | Strong Buy | Maintains | $23 → $27 | -24.11% | Dec 18, 2023 |
| Jefferies | Jefferies | Strong Buy Initiates $31 | Strong Buy | Initiates | $31 | -12.87% | Dec 11, 2023 |
Financial Forecast
Revenue This Year
10.20M
from 886.00K
Increased by 1,051.24%
Revenue Next Year
7.65M
from 10.20M
Decreased by -25.00%
EPS This Year
-3.64
from -49.12
EPS Next Year
-3.24
from -3.64
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 42.0M | 31.5M | n/a | n/a | n/a |
| Avg | 10.2M | 7.7M | n/a | n/a | n/a |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 4,640.4% | 208.8% | - | - | - |
| Avg | 1,051.2% | -25.0% | - | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.10 | -1.88 | -3.69 | -5.72 | -6.46 |
| Avg | -3.64 | -3.24 | -4.39 | -5.56 | -6.27 |
| Low | -7.13 | -4.58 | -5.00 | -5.34 | -6.03 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.